Delivery Order SPE2DB24D1007-SPE2DB25FCCVH
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $13,846.97 on July 28, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count) with a completion deadline of August 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency valued at $27,693.94 on August 15, 2025. The contract involves the supply of Vyndamax 61 mg capsule unit dose packages in quantities of 30, with an ultimate completion date of September 8, 2025. This is a firm fixed price, non-set-aside delivery order with performance at the vendor's Conshohocken facility. The award represents a...
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsules (30-count unit dose packaging) with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract is classified as a non-set-aside and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $83,081.82 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count). This firm fixed price delivery order, which carries an ultimate completion date of September 4, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The award...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $27,693.94 on August 20, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count) under a firm fixed price contract with the Defense Logistics Agency's Medical Supply Chain. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 11, 2025. The contract represents a child award under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count). This order, valued at $13,846.97 with a firm fixed price structure, represents a non-competitive, non-set-aside procurement issued under a delivery order contract type and is scheduled for completion by August 18, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packaging of 30-count bottles. This is a firm fixed price delivery order with a ceiling value of $13,846.97 and an ultimate completion date of August 18, 2025. The contract specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a $27,693.94 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30 count). The contract, with an ultimate completion date of August 20, 2025, employs firm fixed price pricing and carries no set-aside designation, indicating it was competitively awarded. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $13,846.97 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsule unit dose packages (30-count) on August 14, 2025, with an ultimate completion date of September 5, 2025. This non-set-aside award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026. The place of performance...
- The Defense Logistics Agency awarded a $55,387.88 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Vyndamax 61 mg capsules (unit dose, 30-count packages), with completion scheduled for August 22, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract carries no set-aside designation, reflecting AmerisourceBergen's...
- SPE2DB24D1007Indefinite Delivery Contract
- SPE2DB24D1007-SPE2DB25FCCVHDelivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 12, 2025, by the Defense Logistics Agency for the supply of Vyndamax 61 mg capsules in unit dose packs of 30, with a ceiling value of $13,846.97. This firm fixed-price delivery order, which is not set aside for any particular business category, is scheduled for ultimate completion by September 3, 2025. The award represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and running through December 2026, which serves as a comprehensive vehicle for pharmaceutical and medical supply procurement across the military healthcare system. This delivery order exemplifies the ongoing pharmaceutical procurement needs of the Department of Defense through its DLA supply chain, which supports military personnel, veterans, and other federal healthcare beneficiaries. Vyndamax is a branded neurological medication used in the treatment of transthyretin amyloidosis. The competitively awarded order demonstrates AmerisourceBergen Drug Corp's established capability as a critical federal pharmaceutical distributor, leveraging its prime vendor agreement to fulfill specialized medical supply requirements across multiple therapeutic domains in support of military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.8k | 8/12/25 |